Selected article for: "acid sample and acute respiratory disease"
Author: Lu Guo; Xuehan Sun; Xinge Wang; Chen Liang; Haiping Jiang; Qingqin Gao; Moyu Dai; Bin Qu; Sen Fang; Yihuan Mao; Yangcan Chen; Guihai Feng; Qi Gu; Liu Wang; Ruiqi Rachel Wang; Qi Zhou; Wei Li
Title: SARS-CoV-2 detection with CRISPR diagnostics
  • Document date: 2020_4_11
    • ID: 2una9767_3
    Snippet: The novel coronavirus (CoV) disease termed caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) [1] is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic acid detection has played an important role in early diagnosis [2] . To date, 4 protocols based on CRISPR for detecting SARS-CoV-2 have been published [3] [4] [5] [6] . Using lateral flow prot.....
    Document: The novel coronavirus (CoV) disease termed caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) [1] is causing a massive pandemic worldwide, threatening public health systems across the globe. During this ongoing COVID-19 outbreak, nucleic acid detection has played an important role in early diagnosis [2] . To date, 4 protocols based on CRISPR for detecting SARS-CoV-2 have been published [3] [4] [5] [6] . Using lateral flow protocols, RNA samples harboring more than 1 × 10 4 -1 × 10 5 copies/mL (SHERLOCK) or 1 × 10 4 copies/mL (DETECTR) can be detected within 1 hour. In addition to these reported efforts, we have also established a SARS-CoV-2 detection protocol based on our previously reported platform -CDetection (Cas12b-mediated DNA detection) [7] . By combining sample treatment protocols and nucleic acid amplification methods with CDetection, we have established an integrated viral nucleic acid detection platform -CASdetec (CRISPR-assisted detection). The detection limit of CASdetec for SARS-CoV-2 pseudovirus is 1 × 10 4 copies/mL, with no cross reactivity observed. Here we present our assay design and optimization process, which could provide guidance for future CRISPR-based nucleic acid detection assay development and optimization.

    Search related documents:
    Co phrase search for related documents
    • amplification method and cross reactivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • amplification method and detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amplification method and dna detection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amplification method and early diagnosis: 1, 2, 3, 4, 5, 6, 7
    • amplification method and important role: 1
    • assay development and CASdetec detection limit: 1, 2
    • assay development and cross reactivity: 1, 2, 3, 4, 5, 6, 7, 8
    • assay development and detection limit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • assay development and dna detection: 1, 2, 3, 4, 5
    • assay development and early diagnosis: 1, 2, 3, 4, 5, 6, 7
    • assay development and important role: 1, 2, 3, 4, 5, 6, 7, 8
    • assay development and important role play: 1, 2
    • CASdetec detection limit and cross reactivity: 1, 2
    • CASdetec detection limit and detection limit: 1, 2
    • CASdetec detection limit and dna detection: 1, 2
    • CASdetec detection limit and early diagnosis: 1, 2
    • CASdetec detection limit and important role: 1, 2
    • cross reactivity and important role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cross reactivity and important role play: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10